SuperGen, Inc. Announces Filing of Registration Statement for Public Offering of Shares of Common Stock

/in , /by

SuperGen, Inc. Announces Filing of Registration Statement for Public Offering of Shares of Common Stock

SuperGen Completes Submission of New Drug Application (NDA) for Orathecin™ As an Oral Treatment for Pancreatic Cancer

/in , /by

SuperGen Completes Submission of New Drug Application (NDA) for Orathecin™ As an Oral Treatment for Pancreatic Cancer

Published Data Suggests SuperGen’s Nipent®, as Part of a Combination Preparative Regimen, is Active in Allogeneic Bone Marrow Transplant Patients with Myelodysplastic Syndrome

/in , /by

Published Data Suggests SuperGen’s Nipent®, as Part of a Combination Preparative Regimen, is Active in Allogeneic Bone Marrow Transplant Patients with Myelodysplastic Syndrome